<DOC>
<DOCNO>EP-0643052</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Process for enantioselective hydrogenation of 2H-Pyran-2-one derivatives
</INVENTION-TITLE>
<CLASSIFICATIONS>C07B6100	B01J3116	C07B5700	C07D30934	C07D30900	C07D30932	C07B5300	C07B6100	C07B5700	C07B5300	B01J3122	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07B	B01J	C07B	C07D	C07D	C07D	C07B	C07B	C07B	C07B	B01J	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07B61	B01J31	C07B57	C07D309	C07D309	C07D309	C07B53	C07B61	C07B57	C07B53	B01J31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to a novel, catalytic process for the preparation of optically active compounds of the general formula 
<
IMAGE
>
  in which   R
<
1
>
 and R
<
2
>
 in a position other than the  alpha - or ss-position represent alkyl which is optionally interrupted by an O atom or optionally substituted benzyl, R
<
3
>
 is hydrogen, lower alkyl, optionally substituted benzyl, -CO-R
<
4
>
, -COOR
<
4
>
 or -CONR@, and   R
<
4
>
 denotes a lower alkyl or aryl,  by subjecting a compound of the general formula 
<
IMAGE
>
 in which R
<
1
>
, R
<
2
>
 and R
<
3
>
 have the abovementioned meaning to an asymmetric hydrogenation in the presence of a complex of an optically active, preferably atropisomeric, diphosphine ligand with a metal of Group VIII.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BROGER EMIL ALBIN
</INVENTOR-NAME>
<INVENTOR-NAME>
KARPF MARTIN
</INVENTOR-NAME>
<INVENTOR-NAME>
ZUTTER ULRICH
</INVENTOR-NAME>
<INVENTOR-NAME>
BROGER, EMIL ALBIN
</INVENTOR-NAME>
<INVENTOR-NAME>
KARPF, MARTIN
</INVENTOR-NAME>
<INVENTOR-NAME>
ZUTTER, ULRICH
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A process for the enantioselective manufacture of 
optically active compounds of the formula 


 
   wherein 


R
1
 and R
2
signify alkyl with 1 to 17 carbon atoms, which 
is optionally interrupted by an O atom in a 

position other than the α- or β-position, or 
optionally substituted benzyl, 
R
3
signifies hydrogen, lower alkyl with 1 to 5 
carbon atoms, benzyl optionally substituted in 

the 2-, 3-, 4-, 5- and/or 6-position with C
1
-C
5
-alkyl, 
C
1
-C
5
-alkoxy, -CO-R
4
, -COOR
4
 or 
-CONR 4 / 2, and 
R
4
represents a lower alkyl with 1 to 5 carbon 
atoms or a phenyl residue optionally mono- or 

multiply-substituted with C
1
-C
5
-alkyl, C
1
-C
5
-alkoxy 
or halogen, 
 
characterized by asymmetrically hydrogenating a compound of the 

general formula 

 
   wherein R
1
, R
2
 and R
3
 have the significances given above, 
in the presence of a complex of an optically active, atropisomeric 

diphosphine ligand with a metal of Group VIII. 
A process according to claim 1, characterized in that 
the asymmetric hydrogenation is carried out in the presence of an 

optically active ruthenium-diphosphine complex of the formula  
 


[RuL]
2+
(X)
2
[RuLX
2
]
2+
(X)
2
[RuLX
1
X
2
]
+
X
3
RuL(X
4
)2
 
   wherein 


X
signifies BF
4-
, ClO
4-
, B(phenyl)
4-
, SbF
6-
, PF
6-
 or 
Z
1
-SO
3-
, 
X
1
signifies halide, 
X
2
signifies benzene, hexamethylbenzene or p-cymene, 
X
3
signifies halide, ClO
4-
, B(phenyl)
4-
, SbF
6-
, PF
6-
, or 
Z
1
-SO
3-
 or BF
4-
, 
X
4
signifies an anion Z
2
-COO
-
 or an anion Z
3
-SO
3-
, 
Z
1
signifies halogenated lower alkyl with 1 to 4 carbon 
atoms or halogenated phenyl, 
Z
2
signifies lower alkyl with 1 to 5 carbon atoms, 
phenyl, halogenated lower alkyl with 1 to 4 carbon 

atoms or halogenated phenyl, 
Z
3
signifies lower alkyl with 1 to 5 carbon atoms or 
phenyl and 
L
signifies an optically active, atropisomeric 
diphosphine ligand of the formula 


 
or of the general formula 


  
 

   in the (S) or (R) form,
 
   wherein 


R
5
 and R
6
each independently signify lower alkyl, lower 
alkoxy with in each case 1 to 5 carbon atoms, 

di-(C
1
-C
5
-alkyl)-amino, hydroxy, protected 
hydroxy, hydroxymethyl or protected 

hydroxymethyl, or 
R
5
 and R
6
together signify a divalent group
 
―(CH
2
)
q
― , ―CH
2
―O-CH
2
-, 

 
or 


R
7
signifies hydrogen, lower alkyl or lower alkoxy 
with in each case 1 to 5 carbon atoms, 
R
8
 and R
9
each independently represent cyclo-alkyl, 
unsubstituted or substituted phenyl or a 5-membered 

heteroaromatic ring, with the proviso 
that at least one of the residues R
8
 and R
9
 
represents a substituted phenyl ring or a 5-membered 

heteroaromatic ring, 
R
10
represents halogen, hydroxy, methyl, ethyl, 
amino, acetamido, nitro or sulpho, preferably in 

the 5,5'-position, 
R
11
signifies lower alkyl with 1 to 5 carbon atoms, 
phenyl or benzyl, 
R
12
represents lower alkyl with 1 to 5 carbon 
atoms, or both R
12
's together represent a di- or 
trimethylene group, 
p
signifies zero or the number 1, 2 or 3 and 
q
is the number 3, 4 or 5. 
A process according to claim 1 or 2, characterized in 
that the enantioselective hydrogenation is carried out in the  

 
presence of an optically active, diphosphine complex of the 

formula 

[RuL]
2+
(X)
2
 
   wherein X signifies BF
4-
 or CF
3
SO
3-
 and L stands for an 
optically active, atropisomeric ligand of the formula 


 
   in the (R) or in the (S) form,
 
   wherein 


R
5
 and R
6
are the same and signify methyl or methoxy, 
p
is Zero, and 
R
8
 and R
9
are the same and represent a substituted phenyl. 
A process according to any one of claims 1 to 3, 
characterized in that R
8
 and R
9
 in the optically active ligand of 
formula IV have the same significance and represent a residue of 

the formula 

 
   wherein 


R
13
 and R
14
each independently signify lower alkyl, 
lower alkoxy with in each case 1 to 5 

carbon atoms, trialkylsilyl, cyclo-alkyl or 
benzyl or one of the residues R
13
 or R
14
 
also signifies hydrogen, and 
R
15
signifies hydrogen, hydroxy, lower alkyl,  
 

lower alkoxy with in each case 1 to 5 
carbon atoms, trialkylsilyl or di-(lower 

C
1
-C
5
-alkyl)-amino. 
A process according to claim 4, characterized in that 
R
13
 and R
14
 are the same and signify methyl, methoxy, isopropyl, 
tert.-butyl, tert.-pentyl or trimethylsilyl; and R
15
 represents 
hydrogen or methoxy. 
A process according to any one of claims 1 to 5, 

characterized in that the enantioselective hydrogenation of a 
compound of formula II is carried out in a lower alcohol or in a 

mixture of a lower alcohol with ether or water at a temperature 
between 0° to 100°C. 
A process according to any one of claims 1 to 6 for 
the manufacture of compounds of formula I in which R
1
 represents 
a straight-chain alkyl group with 5-17 carbon atoms, R
2
 
represents a straight-chain alkyl group with 1 to 7 carbon atoms 

and R
3
 represents hydrogen by the enantioselective hydrogenation 
of a compound of formula II in the presence of the optically 

active ruthenium-diphosphine complex of formula III-a. 
</CLAIMS>
</TEXT>
</DOC>
